IVIG Therapy for Hypogammaglobulinemia

Patient-Specific Factors

A patient with a history of follicular lymphoma and hypogammaglobulinemia, with an IgG level of less than 500 mg/dL, is a candidate for immunoglobulin replacement therapy to reduce infection risk, according to the American College of Hematology 1, 2
Patients with hematologic malignancies, such as follicular lymphoma, who have received rituximab-containing therapy, are at increased risk of secondary hypogammaglobulinemia and may benefit from IVIG therapy, as recommended by the National Comprehensive Cancer Network 3, 1

The American College of Hematology recommends immunoglobulin replacement therapy for patients with hypogammaglobulinemia and hematologic malignancies when IgG levels are less than 400-500 mg/dL 1, 2
The National Comprehensive Cancer Network suggests that the threshold for IgG replacement could be increased to 650 mg/dL in patients with a history of anti-CD20 therapy, such as rituximab 1
The recommended dosing for IVIG therapy is 0.2-0.4 g/kg body weight every 3-4 weeks to reach a target trough of 600-800 mg/dL, according to the American College of Hematology 2

IVIG replacement therapy is considered standard of care for secondary hypogammaglobulinemia in patients with hematologic malignancies, especially following B-cell depleting therapies like rituximab, as stated by the National Comprehensive Cancer Network 4, 5
Prophylactic immunoglobulin replacement therapy is associated with a significant decrease in major and clinically documented infections in patients with hematologic malignancies and hypogammaglobulinemia, according to the American College of Hematology 1
A multicenter retrospective study demonstrated that IgRT significantly reduced the risk of severe infectious complications in hematologic patients, with a hazard ratio of 0.47 (p = 0.003) 1

IgG levels should be monitored regularly to maintain target trough levels of 600-800 mg/dL, as recommended by the American College of Hematology 2
IVIG therapy should be continued until serum IgG levels normalize and any infections are resolved, according to the National Comprehensive Cancer Network 5
The patient should be reassessed at the planned 6-month follow-up to determine ongoing need based on repeat IgG levels, as recommended by the American College of Hematology 2

Premedication with diphenhydramine and methylprednisolone is appropriate to prevent infusion reactions, as stated by the American College of Chest Physicians 6

The American College of Hematology recommends immunoglobulin replacement therapy for patients with hypogammaglobulinemia when IgG levels are less than 400-500 mg/dL, especially in patients with hematologic malignancies like multiple myeloma 7
Patients with a history of multiple myeloma and previous CAR-T cell therapy are at high risk for severe infections due to immunosuppression, making immunoglobulin replacement therapy necessary 7

The Infectious Diseases Society of America recommends a comprehensive approach including antifungal therapy and immunoglobulin replacement for patients with aspergillus infection and immunodeficiency 8, 9
Continued immunoglobulin therapy is important for patients with successfully treated aspergillosis who require subsequent immunosuppression to prevent recurrence 9, 10

Immunoglobulin replacement therapy has been shown to significantly reduce the risk of severe infectious complications in patients with hypogammaglobulinemia, with a hazard ratio of 0.47 (p = 0.003) 7